BPC-157: What It Is, How It Works, and What the Research Actually Shows

Published: March 2026 | By: Dr. Baghel | Category: Peptide Therapy

BPC-157 was one of seven peptides the FDA reviewed for its compounding list in 2026. I put its human evidence next to the other six in the FDA peptide vote breakdown.

BPC-157 went before the FDA’s compounding committee in July 2026 as one of 7 peptides. The regulatory status is explained in my FDA peptide compounding overview.

BPC-157 is one of the most discussed peptides in regenerative and functional medicine, and one of the most misunderstood. Depending on where you look, it is either a miracle healer or a dangerous, unregulated substance the FDA wants to keep away from patients. The truth is more nuanced than either side suggests.

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids, derived from a protective protein naturally found in human gastric juice. Over three decades of preclinical research have shown effects on tissue repair, inflammation, gut healing, and, critically for psychiatry, the gut-brain axis. The animal data is extensive. The human data is five small studies by the FDA’s count, the largest randomizing 53 ulcerative colitis patients. And nothing that happened in 2026 made it legal to compound.

This article covers what BPC-157 is, how it works, what the preclinical and clinical research actually shows, why it matters to psychiatry through the gut-brain axis, the current FDA and regulatory status, and what patients should understand before considering it.

I’m a board-certified psychiatrist in North Carolina, and I prescribe peptides when federal law allows it. For the ones this article covers, it doesn’t yet. The peptide therapy service page covers where each one stands, what an evaluation includes, and how to schedule a free consultation.

---

Update, July 24, 2026: On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8-6 with 1 abstention to recommend adding BPC-157 to the 503A compounding list for ulcerative colitis. The committee overrode its own FDA reviewers, who had argued the human safety data was too thin to support listing. The FDA hasn’t posted the official meeting record, so the tally comes from RAPS Regulatory Focus. The vote is advisory and non-binding: the FDA still has to accept the recommendation and complete rulemaking before compounding access changes. See my guide to the 2026 FDA peptide decision for what this does and doesn’t change.

What BPC-157 Is and Where It Comes From

BPC-157 is a pentadecapeptide, a chain of 15 amino acids. Its sequence is derived from a larger protein found in human gastric juice that plays a role in maintaining the lining of the stomach. The compound was first isolated in 1993 by Dr. Predrag Sikiric and his research team at the University of Zagreb in Croatia (PMID: 27138887).

Two properties make BPC-157 unusual among peptides.

First, it is remarkably stable in gastric juice, remaining intact for more than 24 hours. Most peptides are rapidly destroyed by stomach acid, which limits oral bioavailability. BPC-157’s stability is why the oral route gets discussed at all, and why the gastrointestinal work used it.

Second, its effects appear to be systemic rather than localized. Preclinical studies have demonstrated activity not just in the gut, but in tendons, ligaments, muscle, bone, the vascular system, and the central nervous system. That broad activity profile is part of what has generated so much interest across multiple medical specialties.

How BPC-157 Works: Mechanisms of Action

BPC-157 does not work through a single pathway. It activates several interconnected biological systems, which accounts for its broad preclinical effects and also makes it more difficult to study in tightly controlled experimental designs.

Angiogenesis (New Blood Vessel Formation)

The primary healing mechanism involves activation of VEGF receptor 2 (VEGFR2). VEGF, or Vascular Endothelial Growth Factor, signals the body to build new blood vessels. More blood flow to damaged tissue means faster delivery of oxygen, nutrients, and immune cells needed for repair. This pathway drives most of BPC-157’s wound healing and tissue repair effects. It is also the mechanism behind the theoretical cancer concern discussed later in this article.

Growth Hormone Receptor Upregulation

In tendon fibroblasts (the cells responsible for tendon repair), BPC-157 increases expression of growth hormone receptors in a dose-dependent and time-dependent manner. When growth hormone then binds to these upregulated receptors, cell proliferation increases through the JAK-2 signaling pathway. This was demonstrated in research on Achilles tendon healing, where BPC-157 treatment enhanced the proliferative response to growth hormone over a three-day period (PMID: 25415472).

Anti-Inflammatory and Nitric Oxide Modulation

BPC-157 reduces inflammatory cytokine production and modulates nitric oxide (NO) synthesis. Rather than simply increasing or decreasing NO levels, it appears to normalize them. This may explain why the compound shows benefit in both inflammatory and ischemic conditions in preclinical models. Nitric oxide plays roles in vasodilation, neurotransmission, and immune regulation, making this pathway relevant to both physical and neurological applications.

Cell Migration and Gene Activation

BPC-157 activates FAK-paxillin complexes, which help cells move to injury sites and anchor themselves for tissue rebuilding. It also stimulates Egr-1 (Early Growth Response gene 1), a transcription factor that acts as a master switch for genes involved in cell growth, survival, and blood vessel formation.

The Gut-Brain Axis: Why BPC-157 Matters to Psychiatry

This is the section most BPC-157 articles skip entirely, and it is the reason a psychiatrist is writing this one.

The gut-brain axis is a bidirectional communication system between the gastrointestinal tract and the central nervous system. The gut produces approximately 90% of the body’s serotonin and a significant portion of its dopamine. When gut health is compromised, whether through inflammation, increased intestinal permeability, or microbial dysbiosis, inflammatory signals can cross into the brain. That neuroinflammation is increasingly recognized as a contributing factor in depression, anxiety, cognitive impairment, and heightened stress reactivity.

BPC-157 interacts with this axis on both ends: peripherally through gut repair, and centrally through neurotransmitter modulation.

Serotonin and Dopamine Effects

A 2016 review in Current Neuropharmacology documented that peripheral administration of BPC-157 (not injected directly into the brain) altered serotonin synthesis rates in specific brain regions, including the hippocampus, hypothalamus, and substantia nigra. After seven days of treatment in animal models, serotonin synthesis patterns shifted in the dorsal raphe nucleus (a primary serotonin production center) and the nucleus accumbens (central to reward processing and mood regulation) (PMID: 27138887).

The dopamine findings are particularly noteworthy. BPC-157 does not simply increase or decrease dopamine activity. It appears to normalize dopaminergic function. In animal studies, it counteracted both amphetamine-induced overstimulation and haloperidol-induced dopamine blockade. That kind of modulatory rather than directional effect is unusual for any compound.

BPC-157’s interactions with the dopaminergic system are also discussed in the context of ADHD neuroscience and emerging treatment research.

GABA, Benzodiazepines, and Serotonin Syndrome

A 2023 follow-up paper in Pharmaceuticals expanded on these findings, describing anxiolytic (anti-anxiety), anticonvulsive, and antidepressant effects in animal behavioral models. The same paper documented that BPC-157 attenuated the development of tolerance and physical dependence during benzodiazepine therapy in rats, and counteracted serotonin syndrome, one of the most serious adverse effects of antidepressant medications (PMID: 37242459).

Neuroprotection

BPC-157 reduced neuronal damage following hippocampal ischemia, mitigated traumatic brain injury progression, promoted peripheral nerve regeneration after transection, and counteracted cuprizone-induced demyelination (a standard model for multiple sclerosis research). In spinal cord compression models, it produced functional recovery in both short-term and long-term follow-up (PMID: 34539999).

The Essential Caveat

No human clinical trials have evaluated BPC-157 for depression, anxiety, PTSD, or any psychiatric condition. The psychiatric implications are extrapolated from animal data and mechanistic reasoning. Patients seeking treatment for depression or anxiety should begin with established, evidence-based approaches. That said, the gut-brain axis research does provide a plausible mechanism for the mood and cognitive improvements some patients report when using BPC-157 for gut healing or injury recovery.

BPC-157 is the peptide patients ask me about most on my peptide therapy page for North Carolina. No US pharmacy can compound it, so I can’t write for it. Almost everyone who asks is already on a vial they bought online. The work is checking what that vial is doing to their labs and their psychiatric medications.

What the Animal Research Shows

The preclinical evidence for BPC-157 is extensive. A 2025 systematic review in HSS Journal screened 544 articles published between 1993 and 2024. After applying inclusion criteria, 36 studies were included: 35 preclinical and 1 clinical (PMID: 40756949). That review counted 1 human study under its orthopaedic inclusion criteria. The FDA’s broader search found 5. Either way the animal literature outweighs the human literature by more than an order of magnitude.

The findings are consistent across multiple tissue types and injury models:

Tendon and ligament injuries. In rat models of Achilles tendon transection, BPC-157 improved biomechanical tendon strength and functional recovery. Healed tendons demonstrated higher load-to-failure measurements, meaning they could withstand more stress before re-rupturing.

Muscle injuries. BPC-157 promoted healing in muscle crush, transection, and denervation injuries, and improved muscle function recovery including counteraction of neuromuscular junction failure.

Bone fractures. In fracture models, BPC-157 promoted callus mineralization and lamellar bone formation rather than fibrous scar tissue. In one model, it performed comparably to autologous bone marrow injection and bone grafting.

Gastrointestinal healing. This is BPC-157’s original and most extensively studied domain. It has shown protective effects against NSAID-induced ulceration, chemotherapy-induced gut damage, and alcohol-induced gastric and liver injury. It was used in early-phase human trials for ulcerative colitis under the designation PL 14736.

Vascular repair. BPC-157 counteracted vessel occlusion syndromes by rapidly activating collateral blood vessel pathways, effectively bypassing occluded or damaged vessels in rat models.

An important methodological note: virtually every published BPC-157 study reports positive results. A 2025 scoping review specifically flagged the possibility of publication bias, meaning negative findings may be going unpublished. This does not invalidate the positive findings, but it does mean the evidence base may appear more uniformly favorable than it actually is.

What the Human Studies Show

Despite three decades of preclinical research, human clinical data on BPC-157 remains extremely limited. The FDA’s reviewers searched PubMed and Embase for the July 2026 briefing and found five clinical studies. Three of those were published only as meeting abstracts. The largest randomized 53 ulcerative colitis patients to a BPC-157 enema in 2005, under the development code PL 14736. The US case series below are the ones most often cited.

Knee pain (2021). Lee and Padgett published a retrospective case series evaluating intra-articular BPC-157 injections for chronic knee pain. Of 16 patients contacted at 6 to 12 months, 14 (87.5%) reported significant pain relief. There was no control group, no common diagnosis among participants, and no functional outcome measures.

Interstitial cystitis (2024). The same research group evaluated bladder injections of BPC-157 in 12 women with moderate-to-severe interstitial cystitis who had failed other treatments. Ten of 12 reported complete symptom resolution at six weeks. No control group. Pilot study design.

IV safety pilot (2025). Lee and Burgess administered intravenous BPC-157 at 10 mg and 20 mg doses to two healthy adults. No adverse effects were observed on cardiac, liver, kidney, thyroid, or glucose biomarkers. Plasma returned to baseline within 24 hours. Two participants total.

Those three US case series are the whole domestic record, and none had a control group or a blind. The only randomized, blinded trial in the FDA’s set is the 2005 ulcerative colitis study, and it exists only as a meeting abstract. No long-term safety data beyond 12 months. No human data on tendon repair, nerve regeneration, or any psychiatric application, and nothing on gut healing since a 2005 ulcerative colitis trial published only as an abstract.

The gap between the robust animal literature and the near-absence of human trials likely reflects regulatory barriers, funding limitations (BPC-157 is not easily patentable, which limits pharmaceutical company interest), and the compound’s restricted regulatory status, which has discouraged institutional research.

FDA Status: Why No Pharmacy Can Compound BPC-157 Today

BPC-157 has never been FDA-approved for any indication. In 2023 the FDA put it in category 2 of its interim compounding policies, citing insufficient human safety data, immunogenicity concerns, and potential risks from peptide-related manufacturing impurities. It came off that list in April 2026, after both of its nominators withdrew their nominations. What keeps it out of a pharmacy now is the statute: BPC-157 meets none of the three conditions section 503A sets for a bulk substance. Outsourcing facilities are no better placed, because it isn’t on the 503B list either.

The World Anti-Doping Agency (WADA) banned BPC-157 effective January 1, 2022, under its S0 “Unapproved Substances” category. The NFL lists it as a prohibited peptide hormone, and the UFC prohibits it at all times.

In February 2026, HHS Secretary Robert F. Kennedy Jr. said he intended to move most of the category 2 peptides back to category 1. Pharmacy Times put the figure at roughly 14 of 19. No FDA action reclassifying those peptides followed.

On April 15, 2026 the FDA gave notice that it would drop 12 peptide bulk substances from category 2, because their nominators had withdrawn the nominations. The removal took effect on April 22. None of them moved to category 1. The count of 12 comes from law-firm analyses of that notice, because the FDA’s own page states no number.

BPC-157 was one of the 12, and it stayed ineligible for compounding throughout. I go through what the 2026 FDA vote did and didn’t change for BPC-157 in more detail.

If the FDA ever adds it to the 503A bulks list, compounding pharmacies could prepare BPC-157 against a valid prescription from a licensed provider. The drug would still be unapproved, and its quality would still depend entirely on the pharmacy that compounded it. The first thing I’d want to know about any vial is where it was made.

If BPC-157 ever becomes eligible, I’d write for it. The FDA would still have to accept the recommendation and complete notice-and-comment rulemaking, so this isn’t a near-term question. When it does arrive, the case for it is a strong mechanistic argument and more than 30 years of animal data. Against it are the 5 small human studies the FDA counted, no human tendon data at all, and an open question about angiogenesis and cancer. For anyone with an active malignancy, a cancer history, or an undiagnosed mass, I wouldn’t offer it.

BPC-157 Side Effects and Safety: What Is Known, Theoretical, and Unknown

The preclinical safety profile of BPC-157 is favorable. Animal studies across multiple organ systems have reported no adverse effects, and no lethal or toxic dose has been established. The published human studies also reported no significant adverse events. However, preclinical safety data from rodents is not the same as established human safety.

The angiogenesis concern. BPC-157 promotes new blood vessel formation. This is therapeutic for wound healing but raises a biologically plausible concern: angiogenesis can also supply blood to tumors, potentially supporting cancer growth. No study has demonstrated that BPC-157 causes cancer. One older in vitro study showed inhibition of a melanoma cell line. But the question has not been systematically investigated. Patients with active cancer, a cancer history, or Von Hippel-Lindau disease should avoid BPC-157 until more data is available.

The sourcing problem. Most BPC-157 currently available to consumers comes from “research chemical” websites with no FDA oversight, no purity testing, no sterility guarantees, and no verified concentrations. This is the single biggest practical risk associated with BPC-157, and it has nothing to do with the peptide itself. It is a supply chain problem. A product from a licensed compounding pharmacy with batch testing would be a different thing entirely from a vial bought off an unregulated website. Right now only the website version exists.

Drug interactions. No human data exists on interactions between BPC-157 and SSRIs, benzodiazepines, antipsychotics, blood thinners, immunosuppressants, or any other medication class. Given BPC-157’s demonstrated effects on serotonin, dopamine, GABA, and nitric oxide systems in animal models, the potential for clinically meaningful interactions is real. Patients taking psychiatric medications should not add BPC-157 without discussing it with their prescribing clinician.

Long-term safety. The longest published human follow-up is 12 months. There are no data on the effects of prolonged use.

Routes of Administration and Dosing

None of this is prescribable today. These figures are here because people are injecting material they bought online, and their clinicians need to know how far those amounts sit from anything that was studied. Subcutaneous injection is the most commonly used route for tissue-targeted effects. Injections are typically administered near the site of injury or into abdominal subcutaneous tissue for systemic distribution.

Oral administration (capsules) is a viable route given BPC-157’s unusual gastric stability. It’s the route the gastrointestinal work used, and absorption kinetics differ from injection.

Intravenous infusion provides the most direct systemic exposure but requires clinical administration and was the route used in the 2025 safety pilot.

The rodent work the FDA reviewed used 10 ng/kg to 10 mcg/kg per day, with repeat-dose toxicity studies running to 4 mg/kg. The human studies used much larger amounts by other routes: an 80 mg rectal enema daily for 2 weeks, 2 to 4 mg into a joint, 10 mg into the bladder, and 10 to 20 mg intravenously. The half-life following injection is less than 30 minutes, indicating rapid clearance. Human dosing remains largely theoretical without completed pharmacokinetic studies.

Who Asks About BPC-157

In clinical practice, patient interest in BPC-157 typically falls into a few categories:

Patients on testosterone replacement therapy who experience joint or tendon pain that limits physical activity or training. Patients with treatment-resistant depression or anxiety who have researched the gut-brain axis and want to address potential neuroinflammatory contributors. And patients with overlapping GI and psychiatric symptoms, a common clinical presentation where chronic gut inflammation may be driving or worsening mood and cognitive symptoms.

For patients whose primary concerns are psychiatric, Semax and Selank have more direct mechanistic relevance to anxiety and depression, through BDNF upregulation and GABAergic modulation respectively. For patients with comorbid gut and mood symptoms, BPC-157 comes up as a question about inflammation. The human evidence isn’t there yet. For patients with musculoskeletal complaints alongside psychiatric care, this is how it usually comes up. An orthopedist or someone at the gym mentions it, and they bring it to me.

BPC-157 is not a standalone treatment for any condition. It belongs inside a plan that already has a real diagnosis, a real primary treatment, and ongoing monitoring. The psychiatric evaluation covers your treatment history, everything you’re currently taking, your labs, and what you’re trying to fix.

Evaluations run by video anywhere in North Carolina, and in person at my Wilmington office by request. If you’re already taking BPC-157, keep the vial and the label in front of you on the call. Where it came from changes what I can tell you about it.

---

Frequently Asked Questions

Is BPC-157 FDA-approved?

No. BPC-157 is not FDA-approved for any indication in the United States. The FDA put it in category 2 of its interim compounding policies in 2023, and it came off that list in April 2026 after its nominators withdrew their nominations. That removal changed nothing about eligibility. On July 23, 2026 an FDA advisory committee voted to recommend adding it to the 503A list. That recommendation would still have to survive notice-and-comment rulemaking before a pharmacy could make it. I go through the rest in my guide to where peptide legality stands after the 2026 FDA vote.

What is BPC-157 used for?

In preclinical research, BPC-157 has shown effects on gastrointestinal healing, tendon and ligament repair, muscle recovery, bone healing, neuroprotection, and vascular repair. The gut-brain axis research also suggests potential relevance to mood and cognition through serotonin and dopamine modulation. However, the vast majority of this evidence comes from animal studies. The FDA counted five small human studies. Only one, a 53-patient ulcerative colitis trial from 2005, was randomized.

Can BPC-157 help with depression or anxiety?

Animal studies show that BPC-157 modulates serotonin and dopamine systems and demonstrates anxiolytic and antidepressant effects in rodent models. The gut-brain axis mechanism is documented in preclinical research. However, no human clinical trials have evaluated BPC-157 for any psychiatric condition. Some patients using BPC-157 for gut healing or injury recovery report mood improvements, but this could reflect placebo response, reduced pain, or improved gut health rather than direct psychiatric action. Evidence-based treatments should remain the first-line approach for depression and anxiety.

What are the side effects of BPC-157?

Preclinical studies report no adverse effects across multiple organ systems, and no lethal dose has been established. The published human studies also reported no significant side effects. Some users report mild nausea, headaches, dizziness, or sleep disruption, particularly at higher doses or with products of uncertain quality. The theoretical cancer risk from angiogenic activity is biologically plausible but unproven. Long-term human safety data does not exist.

Can BPC-157 be taken alongside psychiatric medications?

No human data exists on interactions between BPC-157 and SSRIs, benzodiazepines, antipsychotics, or any other psychiatric medication class. Given its demonstrated effects on serotonin, dopamine, and GABA systems in animal models, the interaction potential is real. Patients should not add BPC-157 to an existing medication regimen without discussing it with their prescribing clinician.

Can a doctor prescribe BPC-157 in North Carolina?

The visit is available anywhere in North Carolina by telehealth. The peptide is a different question. No licensed 503A compounding pharmacy can lawfully prepare BPC-157 right now, so no prescription for it can be filled. At the visit I review what you’re already taking, check it against your psychiatric medications, and order baseline labs.

---

References

1. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887

2. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PMID: 25415472

3. Sikiric P, Gojkovic S, Krezic I, et al. Stable gastric pentadecapeptide BPC 157 may recover brain-gut axis and gut-brain axis function. Pharmaceuticals. 2023;16(5):676. PMID: 37242459

4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PMID: 40756949

5. Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34539999

6. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13.

7. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12-17.

---

Monthly plans cover Dr. Baghel’s clinical services only (evaluation, monitoring, medication management, ongoing care). Labs and medications are paid separately by the patient. Peptide therapy availability depends on current compounding pharmacy regulations. As of August 2026 that means no US pharmacy can make BPC-157. This article is for educational purposes only and is not medical advice. BPC-157 is not FDA-approved for any condition. Do not start, stop, or modify any medication or peptide without consulting your prescribing clinician.